OBSEVA SA (OBSV) Stock Overview

Can you describe the business of OBSEVA SA?

ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women's reproductive health and pregnancy. The company is headquartered in Plan-Les-Ouates, Geneve and currently employs 51 full-time employees. The company went IPO on 2018-07-13. The firm develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: Linzagolix (OBE2109), an oral gonadotropin-releasing hormone (GnRH) receptor antagonist intended for the treatment of endometriosis and uterine fibroids; Nolasiban (OBE001), an oral oxytocin receptor antagonist, with the potential to inhibit uterine contractions at the time of embryo transfer, thereby enhancing embryo implantation during assisted reproductive technologies (ART), and OBE022, an oral and selective prostaglandin F2 alpha (PGF2a) receptor antagonist designed to control preterm labor.

What is the current price of OBSV stock?

The current stock price of OBSV is 0.1018 USD. The price decreased by -15.52% in the last trading session.

Does OBSV stock pay dividends?

OBSV does not pay a dividend.

What is the ChartMill technical and fundamental rating of OBSV stock?

OBSV has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.

Can you provide the PE ratio for OBSV stock?

OBSEVA SA (OBSV) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.79).

Can you provide the market cap for OBSEVA SA?

OBSEVA SA (OBSV) has a market capitalization of 8.60M USD. This makes OBSV a Nano Cap stock.

Can you provide the ownership details for OBSV stock?

You can find the ownership structure of OBSEVA SA (OBSV) on the Ownership tab.